Chiara Zingaretti

This inventor holds 4 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2012-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chiara Zingaretti. Retrieved from https://idiyas.com/inventor/chiara-zingaretti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 3)

% Patents Active = 75.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Ravenna, IT (2012)
Siena, IT (2013 - 2015)

Company Filing History:

4 out of 3,978

Novartis Ag

patents

Years Active: 2012-2015

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9102741 - GAS57 mutant antigens and GAS57 antibodies (2015-08-11),

2. 8858957 - GAS57 mutant antigens and GAS57 antibodies (2014-10-14),

3. 8399651 - Nucleic acids encoding GAS57 mutant antigens (2013-03-19),

4. 8287885 - GAS57 mutant antigens and GAS57 antibodies (2012-10-16),

Title: Chiara Zingaretti: Innovator in Vaccine Development

Introduction

Chiara Zingaretti is a prominent inventor based in Siena, Italy. She has made significant contributions to the field of vaccine development, particularly through her innovative work on GAS57 mutant antigens and antibodies. With a total of 4 patents, her research has the potential to impact therapeutic approaches for treating infections.

Latest Patents

Zingaretti's latest patents focus on GAS57 mutant antigens and GAS57 antibodies. The invention provides mutants of GAS57 (Spy0416) that are unable to cleave IL-8 and similar substrates while still maintaining the ability to induce protection. Additionally, the invention includes antibodies that specifically bind to GAS57 and inhibit its ability to cleave IL-8 and similar substrates. These mutants are useful in vaccine compositions aimed at inducing protection, while the antibodies serve as therapeutics for treating infections.

Career Highlights

Throughout her career, Chiara Zingaretti has worked with leading pharmaceutical companies, including Novartis AG and GlaxoSmithKline Biologicals SA. Her experience in these organizations has allowed her to refine her expertise in vaccine research and development.

Collaborations

Zingaretti has collaborated with notable professionals in her field, including Immaculada Margarit Y Ros and Guido Grandi. These partnerships have contributed to her innovative research and the advancement of her patents.

Conclusion

Chiara Zingaretti's work in developing GAS57 mutant antigens and antibodies showcases her dedication to advancing vaccine technology. Her contributions are poised to make a significant impact in the field of therapeutics for infectious diseases.

Profile summary based on public USPTO records.